BiliaryTractCancer near Golden, CO

Care Philosophy: It is a privilege to care for patients and I am dedicated to treating them how I would like my own family to be treated. It is my highest priority to provide comprehensive, evidence-based and compassionate care to all my patients.

Biography: Dr. Young relocated to Denver in 2005 after completing a two-year surgical oncology fellowship at the John Wayne Cancer Institute in Santa Monica, California. His prior education and training was via general surgery residency at Michigan State University/Grand Rapids, a medical degree at the University of North Dakota, and an undergraduate BA at Concordia College in Moorehead, Minnesota.Dr. Youngs interests include all areas of surgical oncology with emphasis on esophageal, hepatobiliary, gastro-intestinal, melanoma, and sarcomatous disease. He has written, published,and presented nationally and internationally on the surgical treatment of various oncologic diseases. He has conducted basic science research in the field of oncology. He is a member of the American College of Surgeons (ACS), the Society of Surgical Oncology (SSO), the American Society of Clinical Oncology (ASCO), and the American Association for Cancer Research (AACR).

Biography: Henning Schade, MD is an Assistant Member Physician at the Colorado Blood Cancer Institute and part of the Plasma Cell and Lymphoid Disease Groups. Dr. Schade completed his Bone Marrow Transplant Fellowship Program at CBCI in 2017 and joined immediately afterward. Dr. Schade is board certified in Internal Medicine and Oncology and has focused his training in Bone Marrow Transplantation and Malignant Hematology.Dr. Schade was born and raised in Hesse, Germany. He stayed in his hometown near Frankfurt/Main until completion of high school when he decided to join a Catholic church group for a mandatory civilian service. Henning has been dedicated to patient care since he started working with patients and elderly with special needs during this period of civilian service. This inspired him to join nursing school for a 3-year training to become licensed nurse.Soon after he finished nursing school in 1998, he signed up for medical school training. He continued to work as a part-time nurse during this time. After finishing med school in 2006 he joined UK-S-H in Kiel, Germany to initiate training as an internal medicine resident and BMT trainee at the bone marrow transplantation center at MSH Kiel. He stayed there until 2010 when he decided to move to the US to continue training as a physician. Dr. Schade then finished a residency in internal medicine in 2014 at MUSC in Charleston South Carolina. He then joined University of Colorado/Anschutz for a Hematology/Oncology Fellowship. After completion in 2016, he joined Colorado Blood Cancer Institute for dedicated BMT fellowship year.Dr. Schade has published several scientific articles, abstracts and posters at ASCO, ASH and EBMT, including his doctoral thesis about second allogeneic stem cell transplantation in patients with relapsed hematologic malignancy. During his time as an internal medicine resident at MUSC he worked in Dr. Yubin Kang™s lab on Multiple Myeloma cell lines and became interested in translational research. During his fellowship in Hematology/Oncology at the University of Colorado he worked in Brent Palmer's lab and studied PD-1 expression on CD4+ T cells and CMV+ T cells after allogenic stem cell transplantation. The results were published in BBMT in 08/2016. These findings were the fundamental basis for his upcoming research projects.Dr. Schade's research interest is primarily in the treatment of plasma cell and lymphoid diseases. He is the primary investigator for several clinical studies that investigate novel treatment options for patients with Multiple Myeloma and Hodgkin lymphoma. He also has a strong research interest in immune reconstitution after autologous and allogenic stem cell transplantation and has published his research in journals such as BBMT. At The Colorado Blood Cancer Institute he developed an investigator initiated a phase 1 protocol for patients with chemotherapy-refractory AML/MDS using GVHD prophylaxis with posttransplant cyclophosphamide followed by PD-1 inhibition with Nivolumab for consolidation. This protocol now offers a potentially curative treatment option for patients that otherwise would not meet criteria to undergo allogenic stem cell transplantation.Dr. Schade loves to bake all kinds of goodies including sourdough bread, bagels and New York style pizza. He also loves to go fishing with his kids. He loves the outdoors and can be found in the mountains hiking and skiing with his family. Dr. Schade is an enthusiastic fan of the Denver Nuggets and he of course is a big fan of European soccer.